Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 19 min ago
Peer-reviewedCC BY-NC-NDJournal of immunotherapy and precision oncology

State of Precision Oncology: An Australian Perspective.

  • Samrin Liaqat1
  • Muhammad Adnan Khattak2,3
  1. 1Department of Medical Oncology, Alan Walker Cancer Care Centre, Royal Darwin Hospital, Northern Territory, Australia.
  2. 2Department of Medical Oncology, Fiona Stanley Hospital, Perth, Western Australia, Australia.
  3. 3Edith Cowin University, Western Australia, Australia.
Read full textPDFDOICite

Abstract

Precision oncology is redefining cancer therapeutics worldwide. In Australia, the integration of genomic medicine into routine clinical oncology remains inconsistently constrained by fragmented funding mechanisms, regional disparities, and a limited workforce. Understanding these structural and policy challenges is crucial for transitioning toward a sustainable, equitable genomic health ecosystem. This narrative review synthesizes evidence from national policy frameworks, peer-reviewed literature, and translational oncology initiatives to examine the current state of precision oncology in Australia. Key domains of analysis include clinical practice patterns, access and equity, infrastructure, data governance, regulatory oversight, and health-policy reform. Although major initiatives, such as Omico's Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) platform, the ZERO Childhood Cancer Program, and the forthcoming national coordination body Genomics Australia, demonstrate substantial progress, significant implementation barriers persist. Australia stands on the cusp of realizing a genomics-enabled model of cancer care. Consolidation of national governance under Genomics Australia, expansion of Medicare Benefits Schedule reimbursement for comprehensive genomic profiling, and integration of digital-innovation platforms will be pivotal to achieving an internationally replicable model for responsible, population-wide precision oncology.

Related

  1. Primary Bone Vascular Neoplasms: An Integrated Biological Perspective from Bone Pathology to Precision Oncology
    Aikaterini Anetaki, Constantine Anetakis, Ioannis Chaniotakis +4
    CancersPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  2. A modified Delphi study to determine Australian healthcare consumer priorities and consensus for the use of genomics and precision medicine approaches in pregnancy healthcare and research
    T. Grace, S. Hoskins, K. Pringle +5
    medRxivPreprintAll rights reservedFull textObstetrics, gynaecology & paediatricsmedRxiv
  3. Precision surgical oncology for hepatocellular carcinoma
    Takehiro Okabayashi, Motoyasu Tabuchi, Teppei Tokumaru +2
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMC
  4. Unravelling the biological divergence of CD30+ lymphoproliferative disorders with skin involvement: from clinical risk to precision oncology
    Yi Jiang, Yang Wang
    eBioMedicinePeer-reviewedCC BY 4.0General medicineCrossref
  5. Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards
    Yu Fujiwara, Shumei Kato, Razelle Kurzrock
    Hematology/Oncology Clinics of North AmericaPeer-reviewedLicence not stated21 citedOncologyOpenAlex

Cite

BibTeXRIS
BibTeX
@article{liaqat2026state,
  title = {{State of Precision Oncology: An Australian Perspective.}},
  author = {Samrin Liaqat and Muhammad Adnan Khattak},
  journal = {Journal of immunotherapy and precision oncology},
  year = {2026},
  month = nov,
  doi = {10.36401/jipo-25-29},
  url = {https://europepmc.org/article/MED/42999809},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - State of Precision Oncology: An Australian Perspective.
AU  - Samrin Liaqat
AU  - Muhammad Adnan Khattak
PY  - 2026
DA  - 2026/11/05
JO  - Journal of immunotherapy and precision oncology
DO  - 10.36401/jipo-25-29
UR  - https://europepmc.org/article/MED/42999809
AB  - Precision oncology is redefining cancer therapeutics worldwide. In Australia, the integration of genomic medicine into routine clinical oncology remains inconsistently constrained by fragmented funding mechanisms, regional disparities, and a limited workforce. Understanding these structural and policy challenges is crucial for transitioning toward a sustainable, equitable genomic health ecosystem. This narrative review synthesizes evidence from national policy frameworks, peer-reviewed literature, and translational oncology initiatives to examine the current state of precision oncology in Australia. Key domains of analysis include clinical practice patterns, access and equity, infrastructure, data governance, regulatory oversight, and health-policy reform. Although major initiatives, such as Omico's Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) platform, the ZERO Childhood Cancer Program, and the forthcoming national coordination body Genomics Australia, demonstrate substantial progress, significant implementation barriers persist. Australia stands on the cusp of realizing a genomics-enabled model of cancer care. Consolidation of national governance under Genomics Australia, expansion of Medicare Benefits Schedule reimbursement for comprehensive genomic profiling, and integration of digital-innovation platforms will be pivotal to achieving an internationally replicable model for responsible, population-wide precision oncology.
SN  - 2666-2345
SN  - 2590-017X
ER  -